Skip to main content

Table 2 Geometric mean and 95% CI for baseline and year-1 biomarker values and for the year 1 to baseline ratio (change) for cases and controls from the WHI postmenopausal HT trials of estrogen plus progestin (E + P) and estrogen-alone (E-alone)

From: Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases

CHD

 

E + P

E-alone

Difference between cohortsb

Overall case vs. control differencec

 

Cases

Controls

P valuea

Cases

Controls

P valuea

N

206

202

 

152

150

   

B2M (mg/mL)

N = 206, 141d

N = 202, 138d

 

N = 152, 110d

N = 150, 108d

   

Baseline

0.13 (0.06, 0.29)

0.11 (0.06, 0.22)

<.001

0.13 (0.06, 0.32)

0.12 (0.05, 0.27)

0.05

0.44

0.0001

Year 1

0.15 (0.07, 0.31)

0.13 (0.06, 0.27)

0.01

0.15 (0.06, 0.38)

0.14 (0.07, 0.30)

0.04

0.87

0.003

Change

1.04 (0.51, 2.11)

1.03 (0.55, 1.94)

0.68

1.02 (0.48, 2.17)

1.00 (0.60, 1.67)

0.18

0.69

0.67

ORM1 (mg/mL)

N = 204, 139

N = 202, 138

 

N = 133, 96

N = 150, 108

   

Baseline

0.52 (0.27, 1.02)

0.49 (0.27, 0.91)

0.10

0.52 (0.25, 1.08)

0.51 (0.25, 1.02)

0.61

0.52

0.16

Year 1

0.47 (0.24, 0.91)

0.46 (0.22, 0.94)

0.66

0.49 (0.25, 0.96)

0.47 (0.2, 1.08)

0.95

0.97

0.32

Change

0.93 (0.50, 1.71)

0.93 (0.48, 1.78)

0.85

0.93 (0.48, 1.79)

0.91 (0.51, 1.63)

0.41

0.68

0.75

THBS1 (ug/mL)

N = 172, 125

N = 175, 124

 

N = 145, 106

N = 108, 108

   

Baseline

1.98 (0.18, 21.35)

2.10 (0.19, 23.82)

0.44

1.85 (0.24, 14.36)

2.36 (0.24, 23.08)

0.02

0.35

0.14

Year 1

1.98 (0.2, 19.12)

2.16 (0.19, 24.55)

0.27

2.16 (0.27, 17.14)

2.39 (0.25, 23)

0.10

0.95

0.38

Change

0.96 (0.12, 7.96)

0.94 (0.13, 6.67)

0.17

1.24 (0.16, 9.53)

0.97 (0.16, 5.76)

0.08

0.26

0.25

CFD (ug/mL)

N = 204, 139

N = 202, 138

 

N = 150, 108

N = 131, 91

   

Baseline

0.79 (0.35, 1.74)

0.72 (0.37, 1.4)

0.003

0.78 (0.36, 1.67)

0.76 (0.4, 1.45)

0.22

0.27

0.02

Year 1

0.75 (0.32, 1.73)

0.7 (0.34, 1.42)

0.05

0.81 (0.33, 1.98)

0.77 (0.36, 1.65)

0.20

0.75

0.09

Change

0.98 (0.58, 1.65)

0.96 (0.65, 1.43)

0.26

1.04 (0.63, 1.70)

1.01 (0.72, 1.44)

0.22

0.95

0.30

IGFBP1 (ng/mL)

N = 201, 139

N = 201, 138

 

N = 150, 108

N = 145, 105

   

Baseline

10.98 (1.56, 77.48)

10.71 (1.26, 90.8)

0.77

9.21 (1.09, 77.72)

7.61 (0.75, 76.76)

0.19

0.32

0.25

Year 1

15.70 (1.85, 133.37)

15.62 (1.81, 134.43)

0.85

17.67 (1.49, 209.42)

12.52 (0.91, 172.68)

0.06

0.12

0.16

Change

1.63 (0.33, 8.20)

1.40 (0.24, 8.15)

0.41

1.79 (0.37, 8.52)

1.87 (0.27, 12.83)

0.13

0.21

0.38

Stroke

 

E + P

E-alone

Difference between cohorts b

Overall case vs. control difference c

 

Cases

Controls

P value a

Cases

Controls

P value a

N

182

176

 

180

170

   

B2M (mg/mL)

N = 181, 146d

N = 174, 146d

 

N = 179, 141d

N = 170, 134d

   

Baseline

0.12 (0.04, 0.38)

0.11 (0.06, 0.20)

0.02

0.13 (0.06, 0.25)

0.11 (0.06, 0.22)

0.002

0.18

0.003

Year 1

0.12 (0.06, 0.26)

0.11 (0.06, 0.21)

0.03

0.13 (0.06, 0.27)

0.12 (0.06, 0.24)

0.06

0.84

0.001

Change

1.05 (0.33, 3.32)

0.99 (0.69, 1.40)

0.32

1.03 (0.64, 1.65)

1.04 (0.70, 1.56)

0.99

0.20

0.31

IGFBP2 (ng/mL)

N = 171, 136

N = 169, 139

 

N = 164, 128

N = 158, 125

   

Baseline

80.9 (23.63, 276.99)

73.52 (15.27, 353.91)

0.53

72.55 (16.63, 316.48)

67.38 (15.28, 297.04)

0.36

0.85

0.14

Year 1

64.95 (16.88, 249.86)

66.11 (17.02, 256.78)

0.65

60.57 (12.3, 298.34)

57.99 (12.4, 271.3)

0.63

0.64

0.86

Change

0.85 (0.33, 2.17)

0.90 (0.40, 2.04)

0.42

0.86 (0.34, 2.17)

0.91 (0.32, 2.55)

0.15

0.96

0.16

IGFBP4 (ug/mL)

N = 175, 139

N = 170, 139

 

N = 168, 131

N = 164, 128

   

Baseline

0.49 (0.22, 1.08)

0.45 (0.18, 1.09)

0.11

0.48 (0.21, 1.11)

0.43 (0.20, 0.95)

0.03

0.87

0.004

Year 1

0.56 (0.24, 1.35)

0.52 (0.23, 1.16)

0.05

0.57 (0.24, 1.39)

0.5 (0.21, 1.18)

0.01

0.47

0.003

Change

1.05 (0.54, 2.05)

1.05 (0.53, 2.10)

0.76

1.10 (0.59, 2.07)

1.03 (0.55, 1.93)

0.08

0.24

0.59

IGFBP6 (ug/mL)

N = 166, 130

N = 159, 133

 

N = 161, 126

N = 153, 118

   

Baseline

0.15 (0.05, 0.43)

0.14 (0.05, 0.4)

0.56

0.15 (0.04, 0.47)

0.14 (0.04, 0.55)

0.99

0.89

0.55

Year 1

0.14 (0.05, 0.41)

0.13 (0.03, 0.51)

0.53

0.14 (0.04, 0.47)

0.14 (0.03, 0.59)

0.58

0.42

0.60

Change

0.92 (0.31, 2.75)

0.91 (0.25, 3.38)

0.99

0.96 (0.28, 3.31)

0.93 (0.33, 2.61)

0.50

0.86

0.57

HPX (mg/mL)

N = 175, 140

N = 170, 140

 

N = 169, 131

N = 164, 128

   

Baseline

0.55 (0.33, 0.92)

0.54 (0.31, 0.95)

0.93

0.57 (0.31, 1.06)

0.54 (0.31, 0.97)

0.17

0.42

0.19

Year 1

0.52 (0.33, 0.82)

0.52 (0.31, 0.87)

0.95

0.54 (0.32, 0.9)

0.53 (0.33, 0.83)

0.35

0.78

0.42

Change

1.00 (0.64, 1.58)

0.99 (0.64, 1.51)

0.50

1.02 (0.67, 1.55)

1.04 (0.71, 1.52)

0.71

0.38

0.09

  1. aP value from t-test for log-transformed biomarker values.
  2. bFor the P value between cohorts, a linear regression of log-biomarker value on trial, case versus control status and their interaction was fitted. The reported P value is the P value of the interaction.
  3. cFor the P value of overall difference between cases and controls, a linear regression of log-biomarker value on trial and case versus control status was fitted. The reported P value is the P value of the case versus control variable.
  4. dNumber of women at baseline and 1 year, respectively.